Business Context and Reporting Period
Supernus Pharmaceuticals, Inc. (SUPN) filed a Form 8-K on May 7, 2019, to report its financial results for the first quarter ended March 31, 2019. The filing incorporates a press release (Exhibit 99.1) detailing these results and announces a conference call scheduled for May 8, 2019.
Key Financial Metrics
The provided filing text serves as a cover document and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of the Q1 2019 results.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding the company's plans, strategies, and intentions. It explicitly disclaims any obligation to update these statements. Investors are directed to the "Risk Factors" section of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018, for a comprehensive list of risks and uncertainties.
Important Facts for Investor Verification
- Verify the specific Q1 2019 financial figures (revenue, net loss, cash position) in the attached Press Release (Exhibit 99.1), as they are not listed in this 8-K text.
- Review the Form 10-K filed on March 1, 2019, for detailed risk factors referenced in this report.
- Confirm the details of the conference call held on May 8, 2019, for management commentary on the results.